Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 3/20 | 0.32 |
| ▸ | LAP3 | P28838 | 2/20 | 0.32 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8371049 | 0.74 | ALDH1A1 (0.32) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL8371099 | 0.72 | ALDH1A1 (0.30) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL8234804 | 0.71 | ALDH1A1 (0.33) | RNPEPSLC7A5ANPEPALDH1A1TSHR | |
| SCHEMBL11413597 | 0.71 | ALDH1A1 (0.33) | RNPEPSLC7A5ANPEPALDH1A1TSHR | |
| SCHEMBL11890516 | 0.69 | TSHR (0.35) | ANPEPALDH1A1TSHRMAPK1 | |
| SCHEMBL1999059 | 0.69 | TSHR (0.35) | ANPEPALDH1A1TSHRMAPK1 | |
| SCHEMBL11890518 | 0.69 | TSHR (0.35) | ANPEPALDH1A1TSHRMAPK1 | |
| SCHEMBL8375232 | 0.69 | — | — | |
| SCHEMBL21596509 | 0.68 | — | — | |
| SCHEMBL8372194 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055288-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015051725-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-04-16 | — | — | WO | disclosed |